Results 131 to 140 of about 3,001 (154)

Development of an 8-valent <i>Salmonella</i> and <i>Shigella</i> MAPS vaccine. [PDF]

Front Immunol
Boerth EM, Roffler B, Hancock Z, Gong J, MacLennan CA, Zhang F, Lu YJ.   +6 more
europepmc   +1 more source

Comparative GC-MS fingerprint analysis of <i>M. fragrans</i> and <i>M. argentea</i> essential oils: Identifying potential markers for safety and quality control of nutmeg. [PDF]

Food Chem X
Khamnuan S, Intharuksa A, Phrutivorapongkul A, Theansungnoen T, Chaichit S, Thongkhao K, Samutrtai P, Sawangrat K.   +7 more
europepmc   +1 more source

Plant-Based Strategies for Vaccine Development: A Narrative Review of Recombinant Biofactories, Phytochemical Adjuvants, Innovative Delivery Systems, and Insights on Oral and Edible Vaccines. [PDF]

Vaccines (Basel)
Najafi K, Jojani M, Najafi S, Roviello GN.   +3 more
europepmc   +1 more source

Adjuvanted influenza vaccination increases pre-existing H5N1 cross-reactive antibodies and overcomes immune imprinting patterns

Bonifaz MA, Bhavsar D, Siegrist C, Didierlaurent A, Meyer B.   +4 more
europepmc   +1 more source

Pre-existing and cross-reactive immunity to avian influenza H5N1 in humans: Implications for pandemic risk and vaccine strategies.

J Infect
Sanz-Muñoz I, Ciria-Gil CJ, Hernandez M, Santiago C, Elsayed AM, Eiros JM, Martinez-Sobrido L, Nogales A.   +7 more
europepmc   +1 more source

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

Vaccine Journal, 2017
We investigated the role of AS03 A (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines.
Geert Leroux-Roels, David W Vaughn, Frédéric Clement   +2 more
exaly   +2 more sources

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis [PDF]

Human Vaccines and Immunotherapeutics, 2016
In this study we describe the immunogenicity results from a subset of older people (N = 5187) who participated in a Phase 3 randomized, observer-blinded trial of AS03-TIV versus TIV (Fluarix (TM)) ClinicalTrials.gov, NCT00753272).
Jeanne-Marie Devaster, Shelly A McNeil, Geert Leroux-Roels   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

EClinicalMedicine, 2023
Brandon Essink, Guy de Bruyn, Maeva Lefebvre   +2 more
exaly  

Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform

Influenza and Other Respiratory Viruses, 2020
Masafumi Endo, Kohji Ueda
exaly